JP2025504984A5 - - Google Patents
Info
- Publication number
- JP2025504984A5 JP2025504984A5 JP2024545781A JP2024545781A JP2025504984A5 JP 2025504984 A5 JP2025504984 A5 JP 2025504984A5 JP 2024545781 A JP2024545781 A JP 2024545781A JP 2024545781 A JP2024545781 A JP 2024545781A JP 2025504984 A5 JP2025504984 A5 JP 2025504984A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- composition according
- ibudilast
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263305483P | 2022-02-01 | 2022-02-01 | |
| US63/305,483 | 2022-02-01 | ||
| PCT/US2023/011931 WO2023150093A1 (en) | 2022-02-01 | 2023-01-31 | Ibudilast for use in the treatment of post-covid conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504984A JP2025504984A (ja) | 2025-02-19 |
| JP2025504984A5 true JP2025504984A5 (OSRAM) | 2026-02-03 |
Family
ID=85382992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024545781A Pending JP2025504984A (ja) | 2022-02-01 | 2023-01-31 | Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12171752B2 (OSRAM) |
| EP (1) | EP4472631A1 (OSRAM) |
| JP (1) | JP2025504984A (OSRAM) |
| CN (1) | CN118973574A (OSRAM) |
| CA (1) | CA3251194A1 (OSRAM) |
| WO (1) | WO2023150093A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12005049B2 (en) | 2021-07-26 | 2024-06-11 | Medicinova, Inc. | Methods of preventing cancer metastasis |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4828003B2 (ja) | 1998-08-10 | 2011-11-30 | 杏林製薬株式会社 | 多発性硬化症治療薬 |
| MX2007006777A (es) * | 2004-12-06 | 2007-08-06 | Avigen Inc | Ibudilast para tratar dolor neuropatico y sindromes asociados. |
| US20090197823A1 (en) * | 2006-05-09 | 2009-08-06 | Braincells, Inc. | Aliskiren modulation of neurogenesis |
| WO2007142924A1 (en) * | 2006-05-31 | 2007-12-13 | Avigen, Inc. | Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity |
| PT2187882E (pt) | 2007-07-11 | 2013-04-17 | Medicinova Inc | Tratamento de uma doença neurodegenerativa progressiva com ibudilast |
| EP4132521A1 (en) * | 2020-04-06 | 2023-02-15 | MediciNova, Inc. | Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast |
| GB202005890D0 (en) * | 2020-04-22 | 2020-06-03 | Aivivo Ltd | New uses |
| WO2022181219A1 (ja) * | 2021-02-24 | 2022-09-01 | 国立大学法人九州大学 | 新興ウイルス感染症治療薬 |
-
2023
- 2023-01-31 JP JP2024545781A patent/JP2025504984A/ja active Pending
- 2023-01-31 US US18/103,983 patent/US12171752B2/en active Active
- 2023-01-31 WO PCT/US2023/011931 patent/WO2023150093A1/en not_active Ceased
- 2023-01-31 CA CA3251194A patent/CA3251194A1/en active Pending
- 2023-01-31 EP EP23707569.2A patent/EP4472631A1/en active Pending
- 2023-01-31 CN CN202380026154.5A patent/CN118973574A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jermain et al. | Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study | |
| JPH0789851A (ja) | 置換フェネチルアミン類を用いた医薬組成物 | |
| JP7758320B2 (ja) | ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 | |
| JP2025511081A5 (OSRAM) | ||
| Eser et al. | Agomelatine: the evidence for its place in the treatment of depression | |
| Chang et al. | Antidepressant drugs: mechanisms of action and side effects | |
| JP2026512418A (ja) | モノアミン抗うつ薬および短時間作用型サイケデリック剤を含む組合せ | |
| Elmer et al. | The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy | |
| US20230145635A1 (en) | Treatment of menstrual cycle-induced symptoms | |
| MX2008000249A (es) | Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos. | |
| Junkes et al. | MAO inhibitors for treatment-resistant depression: Bringing an updated perspective on pioneering drugs | |
| Michaels et al. | Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors | |
| Uddin et al. | Amphetamines: Potent recreational drug of abuse | |
| Kelmendi et al. | Clinical evidence for the use of methylone in the treatment of PTSD: A case series with long-term follow-up | |
| Srinivasan et al. | Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment | |
| JP2024531799A5 (OSRAM) | ||
| JP2023552833A5 (ja) | 薬物使用障害を治療するための薬剤、薬物使用障害患者による薬物使用の低減における治療のための薬剤、薬物使用障害患者による薬物使用の再発を予防するための治療のための薬剤、薬物使用障害患者による薬物禁断を促進する治療のための薬剤及び薬物使用障害に関連するうつ病又は不安の症状を治療するための薬剤 | |
| Habib et al. | Role of Beta-Blockers as an Effective Cardio protective Agents, an insight in to Tackling with Cardiovascular Diseases (CVDs) and Hypertension | |
| TWI752282B (zh) | 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 | |
| Ivanets et al. | Venlafaxine in the treatment of moderate and severe depression: approaches to increasing treatment efficacy | |
| Suvar | Antidepressants | |
| Vasile et al. | P. 2. c. 002 Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes mellitus | |
| Vilayet et al. | Bupropion toxicity causing refractory cardiogenic shock successfully treated with mechanical circulatory support: a case report | |
| Kowshihan et al. | Effectiveness of Paroxetine in Controlling Anxiety during Tooth Preparation—A Prospective Trial | |
| TW202024040A (zh) | 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途 |